The study aimed to evaluate the safety and tolerability of a study drug in children aged 6 to 17 with mild to moderate plaque psoriasis.
Hightower Clinical conducted a pediatric clinical trial to assess the safety and tolerability of an investigational drug in children with mild to moderate plaque psoriasis.
Plaque psoriasis (psoriasis vulgaris) is the most common form of psoriasis, affecting around 6.7 million adults. It causes thick, scaly, discolored patches—called plaques—on the skin, commonly appearing on the elbows, knees, back, and scalp. In severe cases, it can affect the face, hands, feet, genitals, and legs. These plaques can be itchy, painful, or feel like burning.
Hightower Clinical conducted a clinical study to evaluate the safety and tolerability of a study drug in children aged 6 to 17 with mild to moderate plaque psoriasis, aiming to expand effective care options for pediatric patients.
Not Recruiting
01
Study Name | Protocol Number | Sponsor |
---|---|---|
Plaque Psoriasis | 20200196 | Amgen |
The study aimed to evaluate the safety and tolerability of a study drug in children aged 6 to 17 with mild to moderate plaque psoriasis.
Pediatric patients between the ages of 6 and 17 years who are diagnosed with mild to moderate plaque psoriasis.
No, the study is currently not recruiting participants.